Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

S. Verstovsek; V. Subbiah; L. Masarova; C. Cameron Yin; G. Tang; T. Manshouri; E. Asatiani; N. G. Daver

doi:10.1093/annonc/mdy173

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

S. Verstovsek, V. Subbiah, L. Masarova, C. Cameron Yin, G. Tang, T. Manshouri, E. Asatiani, N. G. Daver

Hematopathology

Research output: Contribution to journal › Letter › peer-review

26 Scopus citations

Original language	English (US)
Pages (from-to)	1880-1882
Number of pages	3
Journal	Annals of Oncology
Volume	29
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdy173
State	Published - Aug 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy173

Cite this

@article{420689b03ab349b1a792d6aef60d32d3,

title = "Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor",

author = "S. Verstovsek and V. Subbiah and L. Masarova and {Cameron Yin}, C. and G. Tang and T. Manshouri and E. Asatiani and Daver, {N. G.}",

note = "Funding Information: This work was supported in part by the National Cancer Institute of Health through the MD Anderson Cancer Center Support Grant CA016672, and Incyte Corporation. Funding Information: SV and NGD receive research funding from Incyte Corporation. The remaining authors have declared no conflicts of interest.",

year = "2018",

month = aug,

doi = "10.1093/annonc/mdy173",

language = "English (US)",

volume = "29",

pages = "1880--1882",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

AU - Verstovsek, S.

AU - Subbiah, V.

AU - Masarova, L.

AU - Cameron Yin, C.

AU - Tang, G.

AU - Manshouri, T.

AU - Asatiani, E.

AU - Daver, N. G.

N1 - Funding Information: This work was supported in part by the National Cancer Institute of Health through the MD Anderson Cancer Center Support Grant CA016672, and Incyte Corporation. Funding Information: SV and NGD receive research funding from Incyte Corporation. The remaining authors have declared no conflicts of interest.

PY - 2018/8

Y1 - 2018/8

UR - http://www.scopus.com/inward/record.url?scp=85053255082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053255082&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy173

DO - 10.1093/annonc/mdy173

M3 - Letter

C2 - 29767670

AN - SCOPUS:85053255082

SN - 0923-7534

VL - 29

SP - 1880

EP - 1882

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this